Bonstein Sara 4

Accession 0001604019-25-000003

CIK 0001104506other

Filed

Jul 8, 8:00 PM ET

Accepted

Jul 9, 4:18 PM ET

Size

21.6 KB

Accession

0001604019-25-000003

Form 4

Period: 2025-07-07

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
2025-07-07$26.43/sh+23,565$622,823→ 128,064 total
Exercise/Conversion
Stock Option (right to buy)
2025-07-07−23,565→ 15,710 total
Exercise: $26.43Exp: 2032-01-06→ Common Stock (23,565 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-07-07−4,362→ 0 total
Exercise: $24.70Exp: 2030-05-12→ Common Stock (4,362 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-07-07−13,717→ 12,023 total
Exercise: $26.46Exp: 2031-05-12→ Common Stock (13,717 underlying)
Exercise/Conversion
Common Stock
2025-07-07$24.70/sh+4,362$107,741→ 104,499 total
Exercise/Conversion
Common Stock
2025-07-07$26.46/sh+13,717$362,952→ 141,781 total
Sale
Common Stock
2025-07-07$96.19/sh−22,181$2,133,590→ 84,017 total
Exercise/Conversion
Stock Option (right to buy)
2025-07-07−6,244→ 18,880 total
Exercise: $19.74Exp: 2033-01-05→ Common Stock (6,244 underlying)
Exercise/Conversion
Common Stock
2025-07-07$19.74/sh+6,244$123,257→ 100,137 total
Sale
Common Stock
2025-07-07$95.66/sh−35,583$3,403,870→ 106,198 total

Footnotes (6)

[F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 5, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
[F2]Includes 357 shares acquired through the Company's 2018 Employee Stock Purchase Plan.
[F3]This is the weighted average sales price representing 35,583 shares sold at prices ranging from $95.01 to $96.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
[F4]This is the weighted average sales price representing 22,181 shares sold at prices ranging from $96.01 to $96.95 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
[F5]The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
[F6]The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.

Documents

1 file

INSMED Inc

CIK 0001104506

Entity typeother